Wells Fargo Maintains Overweight on Insulet, Lowers Price Target to $255

Benzinga Newsdesk www.benzinga.com Negative 90.7%

Neg 90.7% Neu 0% Pos 0%

Wells Fargo analyst Lawrence Biegelsen maintains Insulet (NASDAQ:PODD) with a Overweight and lowers the price target from $360 to $255.